Skip to main content
SpringerLink
Log in

Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen—a Possible Novel Therapeutic Target

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein receptor, is highly expressed in prostate cancer and in the tumor neovasculature of colon, breast, and adrenocortical tumors. Here, we analyzed PSMA expression in the neovasculature of various thyroid cancer subtypes and assessed whether PSMA expression is correlated with aggressive behavior. From a prospectively maintained database, we evaluated 91 samples from 68 patients, including 37 primary differentiated thyroid cancers (DTCs) [11 classic papillary (cPTC), 9 follicular-variant (FvPTC), 11 follicular (FTC), 6 radioactive iodine-refractory (RAIR)], 5 anaplastic (ATC) carcinomas, 9 distant and 12 lymph node metastases, 21 benign thyroid nodules, and 7 normal thyroid specimens. Formalin-fixed paraffin-embedded tissue blocks were immunostained for vascular endothelial marker CD31 and PSMA with proper controls. PSMA expression was not detected in normal thyroid tissue. DTC tumors demonstrated a significantly higher PSMA expression, in regard to both intensity and percentage of vessels stained, than benign tumors (p < 0.001). Among the histologic subtypes, cPTC, FTC, and RAIR carcinomas demonstrated the highest percent of moderate to strong PSMA staining. PSMA expression was seen more frequently in specimens from distant metastases (100%) compared with specimens from only lymph node metastases (67%). PSMA is significantly overexpressed in the neovasculature of DTCs compared with normal and benign thyroid nodules specifically with increased expression in RAIR carcinomas and distant metastases. PSMA should be further explored as a novel therapeutic target for metastatic and RAIR carcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Horn-Ross PL, Lichtensztajn DY, Clarke CA, Dosiou C, Oakley-Girvan I, Reynolds P, Gomez SL, Nelson DO. Continued rapid increase in thyroid cancer incidence in california: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomarkers Prev 2014; 23, 1067–1079.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014 J Natl Compr Canc Netw 2014; 12, 1671–1680; quiz 1680.

    Article  PubMed  Google Scholar 

  3. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008; 62, 559–563.

    Article  CAS  PubMed  Google Scholar 

  4. Hughes DT, Laird AM, Miller BS, Gauger PG, Doherty GM. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Ann Surg Oncol 2012; 19, 2951–2957.

    Article  PubMed  Google Scholar 

  5. Ito Y, Suzuki S, Ito KI, Imai T, Okamoto T, Kitano H, Sugitani I, Sugino K, Tsutsui H, Hara H, Yoshida A, Shimizu K. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]. Endocr J 2016; 63, 597-602.

  6. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59, 3192–3198.

    CAS  PubMed  Google Scholar 

  7. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40, 1754–1761.

    Article  CAS  PubMed  Google Scholar 

  8. Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, Bander NH, Shin SJ. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS 2014; 122, 482–489.

    Article  CAS  PubMed  Google Scholar 

  9. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6, 273–286.

    Article  CAS  PubMed  Google Scholar 

  10. Matejuk A, Leng Q, Chou ST, Mixson AJ. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011; 3, 7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Crowley MJ, Scognamiglio T, Yifang L, Kleiman DA, Beninatio T, Aronova A, He L, Jhanwar YS, Molina A, Tagawa T, Bander NH, Zarnegar R, Elemento O, Fahey TJ. Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. J Clin Endocrinol Metab 2016; 101, 981–987.

    Article  CAS  PubMed  Google Scholar 

  12. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Jr., Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30, 628–636.

    Article  PubMed  Google Scholar 

  13. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84, 1875–1887.

    Article  CAS  PubMed  Google Scholar 

  14. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994; 144, 1188–1194.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3, 81–85.

    CAS  PubMed  Google Scholar 

  16. Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC. Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Appl Immunohistochem Mol Morphol 2017; 25, 271-276.

  17. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25, 540–547.

    Article  CAS  PubMed  Google Scholar 

  18. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 19, 5182–5191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23, 4591–4601.

    Article  CAS  PubMed  Google Scholar 

  20. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4, 128ra139.

    Article  Google Scholar 

  21. Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(6)(8)Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging 2015; 42, 1622–1623.

    Article  PubMed  Google Scholar 

  22. Taywade SK, Damle NA, Bal C. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer? Clin Nucl Med 2016; 41, e263–e265.

    Article  PubMed  Google Scholar 

  23. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, Usadel KH, Hubner K. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 1994; 120, 651–656.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Surgery, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, 10065, USA

    Maureen Moore, Suraj Panjwani, Rashmi Mathew, Michael Crowley, Anna Aronova, Brendan Finnerty, Rasa Zarnegar & Thomas J. Fahey III

  2. Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 10, New York, NY, 10065, USA

    Yi-Fang Liu & Theresa Scognamiglio

Authors
  1. Maureen Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suraj Panjwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rashmi Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Crowley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-Fang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Aronova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Brendan Finnerty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rasa Zarnegar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas J. Fahey III
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Theresa Scognamiglio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theresa Scognamiglio.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moore, M., Panjwani, S., Mathew, R. et al. Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen—a Possible Novel Therapeutic Target. Endocr Pathol 28, 339–344 (2017). https://doi.org/10.1007/s12022-017-9500-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-017-9500-9

Keywords

Search

Navigation